BiondVax Pharmaceuticals Ltd.
BVXVW
BVXVW was delisted on the 13th of May, 2020.
4 hedge funds and large institutions have $127K invested in BiondVax Pharmaceuticals Ltd. in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
2% less capital invested
Capital invested by funds: $130K → $127K (-$3K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.86K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CH
1
CVI Holdings
Wilmington,
Delaware
| $85K | – | – | – |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $26K | +$6.86K | +5,500 | +34% |
|
|
VIA
3
Vantage Investment Advisors
State College,
Pennsylvania
| $14K | – | – | – |
|
4
UBS Group
Zurich,
Switzerland
| $2K | – | – | – |
|
BVXVW Hedge Fund Activity: Q3 2018 in Review
4 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in BiondVax Pharmaceuticals Ltd. (BVXVW) for Q3 2018, worth a combined $127K — down 2.3% from $130K a quarter earlier.
Fund positioning in BVXVW was balanced in Q3 2018: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $6.86K.
- 4 institutional investors held BiondVax Pharmaceuticals Ltd. (BVXVW) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $127K of BiondVax Pharmaceuticals Ltd. stock for Q3 2018, down 2.3% quarter-over-quarter.
- 0 funds opened new BiondVax Pharmaceuticals Ltd. positions in Q3 2018 and 0 closed out.
- The largest BiondVax Pharmaceuticals Ltd. buyer in Q3 2018 was Susquehanna International Group, an estimated $6.86K added.
Based on aggregated 13F filings for Q3 2018.